HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors

被引：0
作者：
Deblock, M. [1 ]
Esterni, B. [1 ]
Tarpin, C. [1 ]
Charaffe-Jauffret, E. [1 ]
Extra, J. M. [1 ]
Viens, P. [1 ]
Goncalves, A. [1 ]
机构：
[1] Inst Paoli Calmettes, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors
    Gilabert, M.
    Esterni, B.
    Bertucci, F.
    Viens, P.
    Goncalves, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
    Livi, Lorenzo
    Bonomo, Pierluigi
    Meattini, Icro
    Simontacchi, Gabriele
    Greto, Daniela
    Desideri, Isacco
    Meacci, Fiammetta
    Scotti, Vieri
    Cecchini, Sara
    Nori, Jacopo
    Sanchez, Luis Jose
    Orzalesi, Lorenzo
    Paiar, Fabiola
    Biti, Gianpaolo
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [23] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
    Lorenzo Livi
    Pierluigi Bonomo
    Icro Meattini
    Gabriele Simontacchi
    Daniela Greto
    Isacco Desideri
    Fiammetta Meacci
    Vieri Scotti
    Sara Cecchini
    Jacopo Nori
    Luis Jose Sanchez
    Lorenzo Orzalesi
    Fabiola Paiar
    Gianpaolo Biti
    Medical Oncology, 2013, 30
  • [24] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Tamura, Kenji
    Inoue, Kenichi
    Masuda, Norikazu
    Takao, Shintaro
    Kashiwaba, Masahiro
    Tokuda, Yutaka
    Iwata, Hiroji
    Yamamoto, Naohito
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakayama, Takahiro
    Sato, Nobuaki
    Toyama, Tatsuya
    Ishida, Takanori
    Arioka, Hitoshi
    Saito, Mitsue
    Ohno, Shinji
    Yamauchi, Hideko
    Yamada, Kimito
    Watanabe, Junichiro
    Ishiguro, Hiroshi
    Fujiwara, Yasuhiro
    CANCER SCIENCE, 2017, 108 (05): : 987 - 994
  • [25] Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy
    Nisman, B
    Barak, V
    Hubert, A
    Kaduri, L
    Lyass, O
    Baras, M
    Peretz, T
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1939 - 1942
  • [26] Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons
    Sini, Valentina
    Cassano, Alessandra
    Corsi, Domenico
    De Laurentiis, Michele
    Gamucci, Teresa
    Mauri, Mariella
    Naso, Giuseppe
    Roselli, Mario
    Ruggeri, Enzo Maria
    Tonini, Giuseppe
    Vici, Patrizia
    Zampa, Germano
    Marchetti, Paolo
    TUMORI JOURNAL, 2016, 102 (05): : 472 - 480
  • [27] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
  • [28] Docetaxel-gemcitabine in patients with HER2-negative metastatic breast cancer pretreated with anthracyclines.
    Bautista Aragon, Y. L.
    Pluma Jimenez, M. A.
    Silva, A. J.
    Perez, M.
    Gutierrez, J. A.
    Villalobos, R.
    Rivera, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [30] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Katherine F. Croom
    Sohita Dhillon
    Drugs, 2011, 71 : 2213 - 2229
12345